Skip to content

Excessive pricing and orphan drugs: Leadiant sanctioned by the Italian Antitrust Authority

Related people
Image of Emilio De Giorgi
Emilio De Giorgi

Partner

Milan

View profile →

Miotto Francesca
Francesca Miotto

Counsel

Brussels

View profile →

09 June 2022

The Italian Antitrust Authority has recently decided that Leadiant infringed Article 102 TFEU through a multifaceted strategy that led to it obtaining an excessive price for its CDCA Leadiant® medicine.

Our alert analyses key aspects of the IAA’s decision and draws out key takeaways for pharmaceutical companies operating in the EU.